Company Overview of Intrexon Corporation
Intrexon Corporation, a biotechnology company, operates in the synthetic biology field in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. Its technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; cell systems informatics; RheoSwitch inducible gene switch; AttSite Recombinases; protein engineering; mAbLogix; and laser-enabled analysis and processing. Intrexon Corporation has collaboration agreements with ZIOPHARM Oncology, Inc.; Synthetic Biologics, Inc.; Oragenics, In...
20374 Seneca Meadows Parkway
Germantown, MD 20876
Founded in 1998
Key Executives for Intrexon Corporation
Chairman, Chief Executive Officer and President
Chief Financial Officer
Total Annual Compensation: $382.2K
Chief Operating Officer
Total Annual Compensation: $2.3M
Head of Health Sector and Senior Vice President
Total Annual Compensation: $485.3K
Senior Vice President of Energy Sector
Total Annual Compensation: $341.0K
Compensation as of Fiscal Year 2014.
Intrexon Corporation Key Developments
Intrexon Corporation Announces Executive Appointments
Jul 21 15
Intrexon Corporation announced three additions to the executive team -- Jack A. Bobo, as Senior Vice President, Chief Communications Officer, Samuel Broder, M.D., as Senior Vice President, Head of Health Sector, and Joel Liffmann as Senior Vice President, Finance. Mr. Bobo joins Intrexon from the U.S. Department of State where he has worked for the past thirteen years, most recently as Senior Advisor for Food Policy following his positions as Senior Advisor for Biotechnology as well as Chief, Biotechnology and Textile Trade Division. Through these key roles Mr. Bobo was responsible for global outreach to foreign audiences and senior foreign officials across a variety of issues and led or participated in bilateral trade discussions and negotiations. Dr. Broder has an extensive career in health and is welcomed back to Intrexon in the role as Head of the Health Sector, succeeding Dr. Gregory Frost. Previously he served as Chairman of the Health Sector and Executive Vice President of Scientific and Public Affairs. Prior to Intrexon, Dr. Broder was Executive Vice President and Chief Medical Officer at Celera and Senior Vice President of Research and Development at IVAX Corporation. He also served as Director of the National Cancer Institute (NCI) for six years. Most recently Mr. Liffmann served as Executive Vice President of Corporate Development at Health Grades Inc., where he was responsible for researching and managing growth initiatives, evaluating and negotiating business opportunities, managing specific legal activities and partnering with other corporate leaders. Prior to Health Grades, Joel was a Senior Advisor to Vestar Capital Partners and was previously a Partner at Oracle Investment Management Inc., where he specialized in private company investing and merchant banking in health care, bioscience, and related industries.
Intrexon Corporation Presents at Third Annual GTL Technology Forum, Jul-29-2015 11:20 AM
Jul 17 15
Intrexon Corporation Presents at Third Annual GTL Technology Forum, Jul-29-2015 11:20 AM. Venue: Norris Conference Centers, City Centre, 816 Town and Country Blvd, Ste 210, Houston, TX 77024, United States. Speakers: Robert F. Walsh, Senior Vice President of Energy Sector.
Intrexon Corporation(NYSE:XON) added to Russell 1000 Index
Jun 30 15
Intrexon Corporation has been added to Russell 1000 Index.
Similar Private Companies By Industry
Recent Private Companies Transactions